Skip to main content

Fiscal Wizard · Single-issue tearsheet

REGN / Aug 13, 2026 Run #13789

REGN

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Composite verdict

A 77.9 / 100
Bullish setup · Trend Following 16 drivers · 2 gates blocking
  • Rate of Change
  • Sushi Roll
  • Accumulation/Distribution Line
Consider long call target Δ ~0.70 · ~35 DTE Bullish setup, Grade A → ITM call target

Industry rank 2nd of 7 in Biotechnology

rescore-sweep
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 15 signals0% Bear
Momentum Bullish 99Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -54%
Asset value $309.05Earnings power value $349.72Price $797.99

Priced above its no-growth earnings power value ($349.72/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

55.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EV/Sales 84
Margin of Safety 0
Greenblatt EY 80
Total Shareholder Yield 0
OCF to Net Income 79
Inventory Turnover 0

Technicals Bullish

100.0 / 100

Bullish setup leads (Rate of Change, Sushi Roll, Accumulation/Distribution Line); bears gated by guards. · 44 signals shown.

Strongest
Weakest
Rate of Change 85
Accumulation/Distribution Line 83
Chaikin Money Flow 81

Risk Gates

2 blocking 5 caution

2 guards active, 26 signals gated.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Current Ratio Caution

Visual liquidity flag — does not mute signals.

Piotroski F-Score Caution

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for REGN.